# EU-1-22-1700_public-assessment-report_20230111_20230111_ebvallo-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
13 October 2022
EMA/858618/2022
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Ebvallo
International non-proprietary name: tabelecleucel
Procedure No. EMEA/H/C/004577/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
7
1.1. Submission of the dossier
7
1.2. Legal basis, dossier content
7
1.3. Information on Paediatric requirements.
7
1.4. Information relating to orphan market exclusivity.
7
1.4.1. Similarity
7
1.5. Applicant's requests for consideration
8
1.5.1. Marketing authorisation under exceptional circumstances
8
1.5.2. Accelerated assessment
8
1.5.3. New active Substance status
8
1.5.4. Scientific recommendation on Classification
8
1.6. PRIME
8
1.7. Protocol assistance
9
1.8. Steps taken for the assessment of the product
9
2. Scientific discussion
11
2.1. Problem statement
11
2.1.1. Disease or condition
11
2.1.2. Epidemiology and risk factors.
11
2.1.3. Biologic features.
11
2.1.4. Clinical presentation and prognosis
11
2.1.5. Management.
12
2.2. About the product
12
2.3. Type of Application and aspects on development
13
2.4. Quality aspects
13
2.4.1. Introduction
13
2.4.2. Active Substance
14
2.4.3. Finished Medicinal Product
18
2.4.4. Discussion on chemical, pharmaceutical and biological aspects
22
2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects
23
2.4.6. Recommendations for future quality development.
23
2.5. Non-clinical aspects
23
2.5.1. Introduction
23
2.5.2. Pharmacology
23
2.5.3. Pharmacokinetics
28
2.5.4. Toxicology
29
2.5.5. Ecotoxicity/environmental risk assessment
30
2.5.6. Discussion on the non-clinical aspects
30
2.5.7. Conclusion on the non-clinical aspects
31
2.6. Clinical aspects
31
2.6.1. Introduction
31
2.6.2. Clinical pharmacology
32
2.6.3. Discussion on clinical pharmacology
35
2.6.4. Conclusions on clinical pharmacology
36
2.6.5. Clinical efficacy
36
Assessment report
EMA/858618/2022
Page 2/87
